Log in
NASDAQ:TBIO

Translate Bio Stock Forecast, Price & News

$12.64
+0.21 (+1.69 %)
(As of 09/24/2020 12:00 AM ET)
Add
Compare
Today's Range
$11.91
Now: $12.64
$12.92
50-Day Range
$12.43
MA: $14.18
$15.87
52-Week Range
$6.80
Now: $12.64
$28.09
Volume1.10 million shs
Average Volume1.07 million shs
Market Capitalization$938.44 million
P/E RatioN/A
Dividend YieldN/A
Beta0.29
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. It has a collaboration and license agreement with Sanofi Pasteur Inc. to develop mRNA vaccines for up to five infectious disease pathogens. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 1.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.24 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TBIO
CUSIPN/A
CIKN/A
Phone617-945-7361

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.80 million
Book Value$2.56 per share

Profitability

Net Income$-113,290,000.00
Net Margins-393.56%

Miscellaneous

Employees81
Market Cap$938.44 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
$12.64
+0.21 (+1.69 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for TBIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Translate Bio (NASDAQ:TBIO) Frequently Asked Questions

How has Translate Bio's stock price been impacted by COVID-19 (Coronavirus)?

Translate Bio's stock was trading at $7.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TBIO stock has increased by 70.1% and is now trading at $12.64.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Translate Bio?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Translate Bio
.

When is Translate Bio's next earnings date?

Translate Bio is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Translate Bio
.

How were Translate Bio's earnings last quarter?

Translate Bio Inc (NASDAQ:TBIO) announced its quarterly earnings data on Thursday, August, 6th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.17. The business earned $16.32 million during the quarter, compared to the consensus estimate of $2.81 million. Translate Bio had a negative return on equity of 54.90% and a negative net margin of 393.56%.
View Translate Bio's earnings history
.

What price target have analysts set for TBIO?

7 brokerages have issued 12 month price objectives for Translate Bio's shares. Their forecasts range from $29.00 to $40.00. On average, they anticipate Translate Bio's stock price to reach $32.50 in the next twelve months. This suggests a possible upside of 157.1% from the stock's current price.
View analysts' price targets for Translate Bio
.

Who are some of Translate Bio's key competitors?

What other stocks do shareholders of Translate Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Translate Bio investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), Moderna (MRNA), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Johnson & Johnson (JNJ) and Heat Biologics (HTBX).

Who are Translate Bio's key executives?

Translate Bio's management team includes the following people:
  • Mr. Ronald C. Renaud Jr., Pres, CEO & Director (Age 50)
  • Dr. Michael W. Heartlein, Chief Technology Officer (Age 60)
  • Mr. John R. Schroer C.F.A., CFA, CFO & Treasurer (Age 54)
  • Dr. Richard Wooster, Chief Scientific Officer (Age 59)
  • Mr. Paul D. Burgess J.D., Chief Legal Officer & Corp. Sec. (Age 45)

When did Translate Bio IPO?

(TBIO) raised $100 million in an initial public offering on Thursday, June 28th 2018. The company issued 7,700,000 shares at a price of $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI served as the underwriters for the IPO.

What is Translate Bio's stock symbol?

Translate Bio trades on the NASDAQ under the ticker symbol "TBIO."

Who are Translate Bio's major shareholders?

Translate Bio's stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (10.55%), FMR LLC (10.55%), RTW Investments LP (5.01%), Vanguard Group Inc. (3.60%), Federated Hermes Inc. (3.58%) and Artal Group S.A. (2.16%). Company insiders that own Translate Bio stock include Baupost Group Llc/Ma, Human Genetic Therapies Shire and Jean Francois Formela.
View institutional ownership trends for Translate Bio
.

Which major investors are selling Translate Bio stock?

TBIO stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, FMR LLC, Perceptive Advisors LLC, Virtus ETF Advisers LLC, and Mitsubishi UFJ Kokusai Asset Management Co. Ltd.. Company insiders that have sold Translate Bio company stock in the last year include Human Genetic Therapies Shire, and Jean Francois Formela.
View insider buying and selling activity for Translate Bio
.

Which major investors are buying Translate Bio stock?

TBIO stock was purchased by a variety of institutional investors in the last quarter, including Artal Group S.A., Vanguard Group Inc., Luminus Management LLC, Alyeska Investment Group L.P., Federated Hermes Inc., Monashee Investment Management LLC, Goldman Sachs Group Inc., and Tudor Investment Corp Et Al.
View insider buying and selling activity for Translate Bio
.

How do I buy shares of Translate Bio?

Shares of TBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Translate Bio's stock price today?

One share of TBIO stock can currently be purchased for approximately $12.64.

How big of a company is Translate Bio?

Translate Bio has a market capitalization of $938.44 million and generates $7.80 million in revenue each year. The company earns $-113,290,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Translate Bio employs 81 workers across the globe.

What is Translate Bio's official website?

The official website for Translate Bio is www.translate.bio.

How can I contact Translate Bio?

Translate Bio's mailing address is 29 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-945-7361.

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.